IP Library › Granted Patent US 9,408,893
Granted Patent B2
US 9,408,893 · App. 13/595,590 · Granted Aug 9, 2016

Pharmaceutical combination for use in glycemic control in diabetes type 2 patients

Inventors: Elisabeth Niemöeller (Frankfurt am Main, DE); Isabel Müehlen-Bartmer (Frankfurt am Main, DE); Louise Silvestre (Paris, FR); Gabor Boka (Paris, FR); Patrick Miossec (Paris, FR)
Assignee: Sanofi-Aventis Deutschland GMBH
A61K38/26A61K31/155A61K31/427A61K31/4439
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,408,893
App. No.
13/595,590
Granted
Aug 9, 2016
Kind
B2
Abstract

The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.

Claims (5)

1. A method for improvement of glycemic control in a patient having diabetes type 2, comprising administering to the patient a therapeutically effective amount of the pharmaceutical combination comprising:

(a) desPro 36 Exendin-4(1-39)-Lys 6 -NH 2 and/or a pharmaceutically acceptable salt thereof, and

(b) a glitazone and/or a pharmaceutically acceptable salt thereof; and

wherein the patient has a haemoglobin A1c (HbA 1c ) value of at least 8% and a fasting plasma glucose of at least 9 mmol/L when treated with glitazone alone.

2. The method of claim 1 , wherein the patient is an adult.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2014
From: NIEMOLLER, ELISABETH; MUHLEN-BARTMER, ISABEL; SILVESTRE, LOUISE; BOKA, GABOR; MIOSSEC, PATRICK
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 033821/0560 →
Priority Claims (1)
EP 11179149 · Aug 29, 2011 · regional
Continuity (1)
Related Publication 20130203666A1 · Aug 8, 2013